These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 25260805)

  • 1. Downregulation of E-cadherin expression in breast cancer by promoter hypermethylation and its relation with progression and prognosis of tumor.
    Shargh SA; Sakizli M; Khalaj V; Movafagh A; Yazdi H; Hagigatjou E; Sayad A; Mansouri N; Mortazavi-Tabatabaei SA; Khorram Khorshid HR
    Med Oncol; 2014 Nov; 31(11):250. PubMed ID: 25260805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer.
    Caldeira JR; Prando EC; Quevedo FC; Neto FA; Rainho CA; Rogatto SR
    BMC Cancer; 2006 Mar; 6():48. PubMed ID: 16512896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of expression and aberrant methylation of the CDH1 (E-cadherin) gene in breast cancer patients from Kashmir.
    Asiaf A; Ahmad ST; Aziz SA; Malik AA; Rasool Z; Masood A; Zargar MA
    Asian Pac J Cancer Prev; 2014; 15(15):6397-403. PubMed ID: 25124632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequent down-regulation of E-cadherin by genetic and epigenetic changes in the malignant progression of hepatocellular carcinomas.
    Matsumura T; Makino R; Mitamura K
    Clin Cancer Res; 2001 Mar; 7(3):594-9. PubMed ID: 11297254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of E-cadherin down-regulation in oral cancer: CDH1 gene expression and epigenetic blockage.
    Pannone G; Santoro A; Feola A; Bufo P; Papagerakis P; Lo Muzio L; Staibano S; Ionna F; Longo F; Franco R; Aquino G; Contaldo M; De Maria S; Serpico R; De Rosa A; Rubini C; Papagerakis S; Giovane A; Tombolini V; Giordano A; Caraglia M; Di Domenico M
    Curr Cancer Drug Targets; 2014; 14(2):115-27. PubMed ID: 24274398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined analysis of E-cadherin gene (CDH1) promoter hypermethylation and E-cadherin protein expression in patients with gastric cancer: implications for treatment with demethylating drugs.
    Graziano F; Arduini F; Ruzzo A; Mandolesi A; Bearzi I; Silva R; Muretto P; Testa E; Mari D; Magnani M; Scartozzi M; Cascinu S
    Ann Oncol; 2004 Mar; 15(3):489-92. PubMed ID: 14998854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic silencing in non-neoplastic epithelia identifies E-cadherin (CDH1) as a target for chemoprevention of lobular neoplasia.
    Zou D; Yoon HS; Perez D; Weeks RJ; Guilford P; Humar B
    J Pathol; 2009 Jun; 218(2):265-72. PubMed ID: 19294736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-specific downregulation and methylation of the CDH13 (H-cadherin) and CDH1 (E-cadherin) genes correlate with aggressiveness of human pituitary adenomas.
    Qian ZR; Sano T; Yoshimoto K; Asa SL; Yamada S; Mizusawa N; Kudo E
    Mod Pathol; 2007 Dec; 20(12):1269-77. PubMed ID: 17873891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines.
    Lombaerts M; van Wezel T; Philippo K; Dierssen JW; Zimmerman RM; Oosting J; van Eijk R; Eilers PH; van de Water B; Cornelisse CJ; Cleton-Jansen AM
    Br J Cancer; 2006 Mar; 94(5):661-71. PubMed ID: 16495925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypermethylation of RARβ2 correlates with high COX-2 expression and poor prognosis in patients with colorectal carcinoma.
    Miladi-Abdennadher I; Abdelmaksoud-Damak R; Ayadi L; Khabir A; Frikha F; Kallel L; Amouri A; Frikha M; Sellami-Boudawara T; Gargouri A; Mokdad-Gargouri R
    Tumour Biol; 2010 Oct; 31(5):503-11. PubMed ID: 20571967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of E-cadherin expression resulting from promoter hypermethylation in oral tongue carcinoma and its prognostic significance.
    Chang HW; Chow V; Lam KY; Wei WI; Yuen A
    Cancer; 2002 Jan; 94(2):386-92. PubMed ID: 11900224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability.
    Sarrió D; Moreno-Bueno G; Hardisson D; Sánchez-Estévez C; Guo M; Herman JG; Gamallo C; Esteller M; Palacios J
    Int J Cancer; 2003 Aug; 106(2):208-15. PubMed ID: 12800196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Negative/low HER2 expression alone or combined with E-cadherin positivity is predictive of better prognosis in patients with breast carcinoma.
    Karray-Chouayekh S; Trifa F; Khabir A; Sellami-Boudawara T; Frikha M; Gargouri A; Mokdad-Gargouri R
    Histol Histopathol; 2012 Mar; 27(3):377-85. PubMed ID: 22237715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypermethylation-modulated down-regulation of CDH1 expression contributes to the progression of esophageal cancer.
    Ling ZQ; Li P; Ge MH; Zhao X; Hu FJ; Fang XH; Dong ZM; Mao WM
    Int J Mol Med; 2011 May; 27(5):625-35. PubMed ID: 21373750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mapping the methylation pattern by bisulfite genomic sequencing of the E-cadherin promoter CpG island in nasopharyngeal carcinoma.
    Kao RH; Huang LC; Hsu YH
    Anticancer Res; 2002; 22(6C):4109-13. PubMed ID: 12553040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. E-cadherin promoter methylation can regulate its expression in invasive ductal breast cancer tissue in Chinese woman.
    Hu XC; Loo WT; Chow LW
    Life Sci; 2002 Aug; 71(12):1397-404. PubMed ID: 12127160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrant methylation of E-cadherin and H-cadherin genes in nonsmall cell lung cancer and its relation to clinicopathologic features.
    Kim DS; Kim MJ; Lee JY; Kim YZ; Kim EJ; Park JY
    Cancer; 2007 Dec; 110(12):2785-92. PubMed ID: 17960794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-derived aberrant methylation in plasma of invasive ductal breast cancer patients: clinical implications.
    Hu XC; Wong IH; Chow LW
    Oncol Rep; 2003; 10(6):1811-5. PubMed ID: 14534701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA methylation and not H3K4 trimethylation dictates the expression status of miR-152 gene which inhibits migration of breast cancer cells via DNMT1/CDH1 loop.
    Sengupta D; Deb M; Rath SK; Kar S; Parbin S; Pradhan N; Patra SK
    Exp Cell Res; 2016 Aug; 346(2):176-87. PubMed ID: 27475839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. δEF1 associates with DNMT1 and maintains DNA methylation of the E-cadherin promoter in breast cancer cells.
    Fukagawa A; Ishii H; Miyazawa K; Saitoh M
    Cancer Med; 2015 Jan; 4(1):125-35. PubMed ID: 25315069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.